US 11,905,495 B2
Treatment compositions comprising cationic poly alpha-1,6-glucan ethers
Mark Robert Sivik, Mason, OH (US); Carola Barrera, West Chester, OH (US); Kristine Lynn Fliter, Harrison, OH (US); Karel Jozef Maria Depoot, Anzegem-Vichte (BE); Wouter Walravens, Humbeek (BE); Cedric Joseph Volont, Laken (BE); Claire Rebecca Yates, Cincinnati, OH (US); Julie Ann Menkhaus, Cleves, OH (US); David Good, Loveland, OH (US); Gang Si, Newcastle upon Tyne (GB); Ruth Chilton, Newcastle upon Tyne (GB); Michael D. Gagnon, West Grove, PA (US); Brandon J. Burkhart, Newark, DE (US); Helen Lu, Wallingford, PA (US); Weiming Qiu, Wilmington, DE (US); and Kathleen Mary McDonough, Mason, OH (US)
Assigned to The Procter & Gamble Company, Cincinnati, OH (US)
Filed by The Procter & Gamble Company, Cincinnati, OH (US)
Filed on Jun. 17, 2021, as Appl. No. 17/350,086.
Claims priority of provisional application 63/040,554, filed on Jun. 18, 2020.
Claims priority of application No. 20183889 (EP), filed on Jul. 3, 2020.
Prior Publication US 2021/0395649 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C11D 3/37 (2006.01); C11D 3/22 (2006.01); C11D 3/00 (2006.01); C11D 11/00 (2006.01); C11D 17/00 (2006.01); C11D 17/04 (2006.01); C11D 17/06 (2006.01); C11D 1/00 (2006.01)
CPC C11D 3/227 (2013.01) [C11D 1/00 (2013.01); C11D 3/0015 (2013.01); C11D 3/0036 (2013.01); C11D 3/22 (2013.01); C11D 3/222 (2013.01); C11D 11/0017 (2013.01); C11D 11/0023 (2013.01); C11D 17/0008 (2013.01); C11D 17/043 (2013.01); C11D 17/044 (2013.01); C11D 17/045 (2013.01); C11D 17/06 (2013.01)] 13 Claims
 
1. A treatment composition comprising:
a poly alpha-1,6-glucan ether compound comprising a poly alpha-1,6-glucan substituted with at least one positively charged organic group,
wherein the poly alpha-1,6-glucan ether compound is characterized by:
(a) a weight average molecular weight of from about 1000 to about 150,000 daltons,
(b) a backbone of glucose monomer units wherein greater than or equal to 65% of the glucose monomer units are linked via alpha-1,6-glycosidic linkages,
(c) from about 35% to about 45%, of the glucose monomer units have branches via alpha-1,2-glycosidic linkages, and
(d) a degree of cationic substitution of about 0.001 to about 3.0;
the treatment composition further comprising a treatment adjunct ingredient;
wherein the treatment composition is a fabric care composition, a dish care composition, or a mixture thereof.